Drug Profile
Research programme: infectious disease DNA vaccines - Wyeth
Latest Information Update: 19 Oct 2009
Price :
$50
*
At a glance
- Originator Wyeth
- Developer Pfizer
- Class DNA vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Bacterial infections; Viral infections
Most Recent Events
- 15 Oct 2009 Wyeth has been acquired by Pfizer
- 31 Mar 2009 Preclinical trials in Bacterial infections in USA (IM)
- 31 Mar 2009 Preclinical trials in Viral infections in USA (IM)